Evidence map›Paper›PMID 39747150›Full record

ArticleScientific reports2025

CDC40 suppression induces CDCA5 splicing defects and anti-proliferative effects in lung cancer cells.

Die Hu, Brigitte L Thériault, Vida Talebian, Laurent Hoffer, Julie Owen, Justin Lim, Benjamin J Blencowe, Evelyne Lima-Fernandes, Punit Saraon, Richard Marcellus and 1 more

Abstract read
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Die HuDrug Discovery Program, Ontario Institute for Cancer Research, Toronto, ON, M5G 0A3, Canada.
Brigitte L ThériaultDrug Discovery Program, Ontario Institute for Cancer Research, Toronto, ON, M5G 0A3, Canada.
Vida TalebianDrug Discovery Program, Ontario Institute for Cancer Research, Toronto, ON, M5G 0A3, Canada.
Laurent HofferDrug Discovery Program, Ontario Institute for Cancer Research, Toronto, ON, M5G 0A3, Canada.
Julie OwenDrug Discovery Program, Ontario Institute for Cancer Research, Toronto, ON, M5G 0A3, Canada.
Justin LimDonnelly Centre for Cellular and Biomolecular Research, University of Toronto, Toronto, ON, M5S 3E1, Canada.
Benjamin J BlencoweDonnelly Centre for Cellular and Biomolecular Research, University of Toronto, Toronto, ON, M5S 3E1, Canada.
Evelyne Lima-FernandesDrug Discovery Program, Ontario Institute for Cancer Research, Toronto, ON, M5G 0A3, Canada.
Punit SaraonDrug Discovery Program, Ontario Institute for Cancer Research, Toronto, ON, M5G 0A3, Canada.
Richard MarcellusDrug Discovery Program, Ontario Institute for Cancer Research, Toronto, ON, M5G 0A3, Canada.
Rima Al-AwarDrug Discovery Program, Ontario Institute for Cancer Research, Toronto, ON, M5G 0A3, Canada. ralawar@oicr.on.ca.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

High mortality and low response rates in lung cancer patients call for novel therapeutic targets. Data mining of whole-genome genetic dependency screens suggest Cell Division Cycle 40 (CDC40) to be an essential protein for lung cancer cell survival. We characterized CDC40 knockdown effects in multiple lung cancer cell lines, revealing induced cell cycle defects that resulted in strong growth inhibition and activation of apoptosis. Global transcriptional and splicing changes were also investigated, where CDC40 knockdown resulted in perturbation of splicing- and translation-related genes as well as more transcripts with intron retention. In the transcript of the cell cycle regulatory protein CDCA5, CDC40 knockdown was shown to induce retention of the first intron, leading to an increase in the unspliced CDCA5 transcript and subsequent decrease in CDCA5 protein expression. Additionally, protein-protein interactions of CDC40 were explored and spliceosome components were found to be its main binding partners, further highlighting the role of CDC40 in splicing. CDC40 mutation analysis suggests that it may be difficult to disrupt key interactions using small molecules within a large complex. Our results demonstrate that CDC40 is essential for lung cancer cell growth, and that its inhibition may represent a viable therapeutic strategy for lung cancer.

Indexed as

Cell Cycle ProteinsCell ProliferationLung NeoplasmsRNA SplicingAdaptor Proteins, Signal TransducingApoptosisCell Line, TumorGene Expression Regulation, NeoplasticGene Knockdown TechniquesHumansAdaptor Proteins, Signal TransducingCDCA5 protein, humanCell Cycle Proteins

Identifiers

PMID39747150
PMCPMC11696760

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.